Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study

References

• Portenoy RK. Managing cancer pain poorly responsive to systemic opioid therapy. Oncology (Huntingt) 1999;13(5 Suppl 2):25–9
   Google Scholar
• American Society of Anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology 1996;84:1243–57
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Expert Committee. Cancer pain relief and palliative care. Geneva: World Health Organization, 1990. Technical report series, No. 804
   Google Scholar
• Agency for Healthcare Research and Quality. Management of Cancer Pain. Summary, Evidence Report/Technology Assessment: Number 35. Rockville, MD: Agency for Healthcare Research and Quality, 2001 January. AHRG Publication No. 01–E033
   Google Scholar
• Data on file. Endo Pharmaceuticals Inc. 2002
   Google Scholar
• Sinatra RS, Hyde NH, Harrison DM. Oxymorphone revisited. Semin Anesth 1988;7(3):209–15
   Google Scholar
• Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy [in press]
   Google Scholar
• Ferrell B, Wisdom C, Wenzl C, Brown J. Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 1989;16(4):521–6
   PubMedGoogle Scholar
• Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995;76(7):1283–93
   PubMed Web of Science ®Google Scholar
• Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19(9):2542–54
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain 2003;19(5):286–97
   PubMedGoogle Scholar
• Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86(9):1856–66
   PubMed Web of Science ®Google Scholar
• Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;20(1):348–52
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med (Singapore) 1994;23:129–38
   PubMedGoogle Scholar
• Karnofsky D, Burchenal J. The clinical evaluation of chemo-therapeutic agents in cancer. In: MacLeod C, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 196
   Google Scholar
• Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg 2000;90(4):933–7
   Google Scholar
• Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73(2):151–7
   PubMed Web of Science ®Google Scholar
• Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the ‘address’ recognition locus. J Med Chem 2001;44(6):857–62
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E, Olkkola KT. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64(6):603–11
   Google Scholar
• Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53(4):401–9
   Google Scholar
• Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17(2):102–5
   Google Scholar
• Flockhart DA. Cytochrome P450 Drug Interaction Table. Available at http://medicine.iupui.edu/flockhart/ [Accessed 30 May 2003]
   Google Scholar
• Heiskanen TE, Ruismaki PM, Seppala TA, Kalso EA. Morphine or oxycodone in cancer pain? Acta Oncol 2000;39(8):941–7
   PubMed Web of Science ®Google Scholar
• Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992;49(1):87–91
   PubMed Web of Science ®Google Scholar
• Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79(7):1428–37
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73(1):37–45
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;16(10):3222–9
   PubMed Web of Science ®Google Scholar
• Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19(11):2898–904
   PubMed Web of Science ®Google Scholar
• Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing. Conversion dilemmas. J Pain Symptom Manage 2001;21(5):397–406
   PubMed Web of Science ®Google Scholar
• Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002;5(1):127–38
   PubMedGoogle Scholar
• Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002;18(4 Suppl):S3–13
   PubMed Web of Science ®Google Scholar
• Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE, Fitzmartin RD. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage 1997;13(2):75–82
   PubMed Web of Science ®Google Scholar
• Dhaliwal HS, Sloan P, Arkinstall WW, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage 1995;10(8):612–23
   PubMed Web of Science ®Google Scholar
• Kloke M, Rapp M, Bosse B, Kloke O. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Supportive Care Cancer 2000;8(6):479–86
   Google Scholar
• Sloan PA, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998;16(2):102–11
   Google Scholar